Skip to main content
GCAN
OTC Life Sciences

Trafalgar Eliminates 481M Potential Common Shares via Preferred Conversion Removal

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Neutral
Importance info
7
Price
$0.47
Mkt Cap
$467.358K
52W Low
--
52W High
--
52W Position
Off High
Rel. Volume
Market data snapshot near publication time

Summary

Trafalgar International's restated charter eliminates preferred conversion rights that represented 481.4 million potential common shares, while authorizing 2 billion new common shares and locking in Series B's 51% voting control.


Key Events · Corporate Governance and Compliance · GCAN

  • Conversion Rights Eliminated

    Series A (7,628,665 shares at 50:1) and Series B (1,000 shares at 100,000:1) conversion rights extinguished, removing 481,433,250 potential common shares from the overhang.

  • Authorized Capital Expanded

    New charter authorizes 2,000,000,000 common shares and 20,000,000 preferred shares, up from prior levels — future issuance capacity remains substantial.

  • Series B Voting Control Locked

    Series B retains at least 51% of aggregate voting power on a fully diluted basis, with automatic adjustment as the voting base changes; Series A loses its 1.76 votes per share.

  • Series A Rights Stripped

    Series A loses general voting rights, liquidation preference, and accrued dividend entitlement; dividends become discretionary.


Analysis · GCAN · Life Sciences

The restated charter removes conversion rights on Series A and Series B preferred stock that could have created 481.4 million common shares — a massive overhang elimination for a company with only 199,153 common shares outstanding. However, the same restatement authorizes 2 billion common shares and 20 million preferred shares, leaving the door open for future dilution. Series B retains permanent 51% voting control, cementing Trafalgar Asset Management's grip on the company. The filing quantifies what the prior 8-K only described qualitatively.

How filings like this one have moved

In the 30 days to Nov 2, 2026, 32.7% of the 1910 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GCAN was trading at $0.47 on OTC in the Life Sciences sector, with a market capitalization of approximately $467.4K. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GCAN - Latest Insights

GCAN
Oct 13, 2026, 6:02 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.470
Real-time Price: $0.470 info
Change: $0 (0%) info
Market Cap: $467.358K info
GCAN
Aug 14, 2026, 1:44 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.2301
Real-time Price: $0.470 info
Change: Reverse Stock Split info
Market Cap: $467.358K info
GCAN
Jul 31, 2026, 2:18 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.220
Real-time Price: $0.470 info
Change: Reverse Stock Split info
Market Cap: $467.358K info
GCAN
Jul 06, 2026, 5:21 PM EDT
Filing Type: SC 14F1
Importance Score:
9
Price at Filing: $0.19405
Real-time Price: $0.470 info
Change: Reverse Stock Split info
Market Cap: $467.358K info
GCAN
Jul 06, 2026, 5:03 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $0.19405
Real-time Price: $0.470 info
Change: Reverse Stock Split info
Market Cap: $467.358K info